Researchers at NIH/NICHD have identified approximately 200 proteins as candidate molecules (leads) that “fine tune” T cell receptor (TCR) signaling. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks partners to collaborate on in vitro studies to validate these potential immunomodulators and to conduct in vivo studies in a murine cancer model to determine the effects of ligands (e.g. antibodies) to the proteins to determine their effect on the immune response to cancer cells. Preference will be given to responses received by March 31, 2016.
Agents that modify the immune response to cancer cells could be used in conjunction with other immunomodulators or therapeutic agents, such as vaccines
Paul Love (NICHD), J. Pinkhasov (NICHD), Z. Li (NICHD)
- Research Material: NIH will not pursue patent prosecution for this technology